Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Myeloma: next generation immunotherapy

Adam D. Cohen

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 266–272.

https://doi.org/10.1182/hematology.2019000068

Published: 2019

Journal Articles

CAR T-cell therapy: is it prime time in myeloma?

Surbhi Sidana, Nina Shah

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 260–265.

https://doi.org/10.1182/hematology.2019000370

Published: 2019

Journal Articles

What to do with minimal residual disease testing in myeloma

Elisabet E. Manasanch

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 137–141.

https://doi.org/10.1182/hematology.2019000080

Published: 2019

Journal Articles

Roundtable: How I treat a newly diagnosed patient with high-risk myeloma

Jonathan L. Kaufman

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 120–124.

https://doi.org/10.1182/hematology.2019000015

Published: 2019

Journal Articles

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana, Elisabet Manasanch

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 142–147.

https://doi.org/10.1182/hematology.2019000075

Published: 2019

Journal Articles

How I treat a refractory myeloma patient who is not eligible for a clinical trial

Siyang Leng, Divaya Bhutani, Suzanne Lentzsch

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 125–136.

https://doi.org/10.1182/hematology.2019000016

Published: 2019

Journal Articles

Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist

Thierry Facon, Kenneth Anderson

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 83–87.

https://doi.org/10.1182/asheducation-2018.1.83

Published: 2018

Journal Articles

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist

Tanya M. Wildes, Kenneth C. Anderson

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 88–96.

https://doi.org/10.1182/asheducation-2018.1.88

Published: 2018

Journal Articles

Treatment approach for young, fit, newly diagnosed multiple myeloma patients

Saad Z. Usmani, Eric Seifter

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 97–102.

https://doi.org/10.1182/asheducation-2018.1.97

Published: 2018

Journal Articles

Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients

Sergio Giralt, Eric Seifter

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 103–109.

https://doi.org/10.1182/asheducation-2018.1.103

Published: 2018

Journal Articles

Is molecular remission the goal of multiple myeloma therapy?

Faith E. Davies

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 205–211.

https://doi.org/10.1182/asheducation-2017.1.205

Published: 2017

Journal Articles

Fixed duration vs continuous therapy in multiple myeloma

Heinz Ludwig, Niklas Zojer

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 212–222.

https://doi.org/10.1182/asheducation-2017.1.212

Published: 2017

Journal Articles

Management of multiple myeloma in the newly diagnosed patient

María-Victoria Mateos, Jesús F. San Miguel

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 498–507.

https://doi.org/10.1182/asheducation-2017.1.498

Published: 2017

Journal Articles

Management of multiple myeloma in the relapsed/refractory patient

Pieter Sonneveld

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 508–517.

https://doi.org/10.1182/asheducation-2017.1.508

Published: 2017

Journal Articles

Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies

Shaji Kumar

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 518–524.

https://doi.org/10.1182/asheducation-2017.1.518

Published: 2017

Journal Articles

Shall we treat smoldering multiple myeloma in the near future?

Ola Landgren

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 194–204.

https://doi.org/10.1182/asheducation-2017.1.194

Published: 2017

Journal Articles

Role of stem cell transplant and maintenance therapy in plasma cell disorders

Philip L. McCarthy, Sarah A. Holstein

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 504–511.

https://doi.org/10.1182/asheducation.V2016.1.504.088352

Published: 2016

Journal Articles

Myeloma: management of the newly diagnosed high-risk patient

Angela Dispenzieri

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 485–494.

https://doi.org/10.1182/asheducation-2016.1.485

Published: 2016

Journal Articles

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Andrew J. Yee, Noopur S. Raje

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 495–503.

https://doi.org/10.1182/asheducation-2016.1.495

Published: 2016

Journal Articles

Advances and practical use of monoclonal antibodies in multiple myeloma therapy

Hans C. Lee, Donna M. Weber

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 512–520.

https://doi.org/10.1182/asheducation-2016.1.512

Published: 2016

NARROW

Myeloma: next generation immunotherapy

CAR T-cell therapy: is it prime time in myeloma?

What to do with minimal residual disease testing in myeloma

Roundtable: How I treat a newly diagnosed patient with high-risk myeloma

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

How I treat a refractory myeloma patient who is not eligible for a clinical trial

Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist

Treatment approach for young, fit, newly diagnosed multiple myeloma patients

Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients

Is molecular remission the goal of multiple myeloma therapy?

Fixed duration vs continuous therapy in multiple myeloma

Management of multiple myeloma in the newly diagnosed patient

Management of multiple myeloma in the relapsed/refractory patient

Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies

Shall we treat smoldering multiple myeloma in the near future?

Role of stem cell transplant and maintenance therapy in plasma cell disorders

Myeloma: management of the newly diagnosed high-risk patient

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Advances and practical use of monoclonal antibodies in multiple myeloma therapy

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only